Podcasts about clinical care

Dr. Brooke Salzman discusses Antiracist Approaches to Clinical Care, which she wrote as part of the free Antiracism Module funded by the Josiah Macy Jr. Foundation. She talks about how to recognize and focus on biases; admitting and addressing our own biases, which is a critical step in becoming antiracist; the importance of diversifying the healthcare workforce by including representation, which is an effective way to improve access to care and reduce disparities; interprofessional teamwork; competencies to foster mutual respect; responding to racist patients; the necessity for organizations to have clear policies that protect staff, among other topics.    

Logan Clinical Care Pharmacist Joe Tabler (4-24-25)

The last few years have seen “a remarkable change in both our approach and management of EGFR lung cancer,” says Shirish M. Gadgeel, MD, division head for hematology/oncology and associate director of Patient Experience and Clinical Care at the Henry Ford Cancer Institute in Detroit. He discusses key considerations for managing EGFR-mutated non-small cell lung cancer with Robert A. Figlin, MD, the interim director and Steven Spielberg Family Chair in Hematology-Oncology at Cedars-Sinai Cancer Center in Los Angeles. Dr. Gadgeel describes considerations for leptomeningeal metastases, important treatment toxicities, and exciting advances on the horizon. Dr. Gadgeel reported various financial relationships. Dr. Figlin reported various financial relationships.

Why is it useful to sometimes “consult” with your patient's parents. What tests you should really never do and why cant we just make everyone happy

In the final episode of our serious on research in Children's Palliative Care, join Rachel Neufeld, a nurse practitioner and Two Worlds Cancer Collaboration volunteer, in conversation with nursing researcher Gail Andrews, research manager at Canuck Place Children's Hospice, as they discuss translating knowledge into clinical care.

Please visit answersincme.com/TDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in metabolic diseases discusses metachromatic leukodystrophy (MLD). Upon completion of this activity, participants should be better able to: Explain the clinical burden and unmet needs in MLD; Describe the signs and symptoms of MLD to facilitate early diagnosis and intervention; and Outline potential strategies to optimize outcomes for patients with MLD.

Distracting injuries can be tricky but should always be taken into account. What should you think about in a child with LLQ abdominal pain and odd Neurological complaints and more about giving yourself a break. 

Exercise and a better diet, prior to surgery, can improve outcomes. Daniel McIsaac, a professor of anaesthesiology from the University of Ottowa and lead author of that research, joins us to talk about getting those results into practice. Julia Sinclair, professor of addiction psychiatry at the University of Southampton, explains how the NHS has lost sight of the impact alcohol consumption has on clinical care, and why we need a strategy to tackle it. Finally, Matt Morgan, consultant in intensive care and BMJ columnist, has written another book - this time about patients who are revived after cardiac arrest, and the profound effect it can have on their outlook in life.    Reading list: Relative efficacy of prehabilitation interventions and their components UK needs national strategy to tackle alcohol related harms A Second Act  

Send us a textWhat transformative impact has technology had on healthcare? Jodi Long, an esteemed healthcare professional from Orlando, Florida, sheds light on her journey in nursing since 1997. Discover how the transition from paper records to sophisticated electronic health systems has not only boosted efficiency and safety in patient care but also introduced new challenges for bedside clinicians. Our conversation navigates the crucial balance between honing clinical skills and embracing technological demands, ensuring that patient care remains paramount despite any tech disruptions.With the advent of electronic health records, patient care has seen a marked improvement through enhanced communication and accessibility. However, the journey isn't without its hurdles, particularly concerning interoperability between disparate health systems. We delve into the role of professional organizations like the Florida Nurses Association in nurturing career development and advocacy and the importance of continuous learning in this rapidly evolving field. Leadership and gender disparity within healthcare also take center stage, as we discuss how the underrepresentation of women in high-level roles is gradually changing for the better.Leadership in healthcare technology is not just about bridging gaps but also about empowering the workforce. We emphasize the significance of mentorship and skill development, especially in addressing workforce shortages. The upcoming Women in IT event promises to be a platform for challenging the status quo and fostering impactful change. As we wrap up, we extend a warm invitation for listeners to continue the conversation on LinkedIn, fostering a community that thrives on shared stories and experiences in the healthcare and IT sectors.Thanks for tuning in to this episode of Follow The Brand! We hope you enjoyed learning about the latest marketing trends and strategies in Personal Branding, Business and Career Development, Financial Empowerment, Technology Innovation, and Executive Presence. To keep up with the latest insights and updates from us, be sure to follow us at 5starbdm.com. See you next time on Follow The Brand!

There's been a massive gap in oncology where people who have been responsible for a dramatic increase in the standard of care have lacked a solid understanding of the business, payment and policy constructs required to deliver it. Dr. Stephen Schleicher has spent the early part of his career working to fill that gap.Dr. Schleicher entered medical school with an interest in oncology, anchored by an appreciation for the psychological toll cancer can have on a person, their family and caregivers that he gained from parents who were both psychologists. During his internal medicine residency at Brigham and Women's Hospital, Dr. Schleicher also worked at McKinsey and earned his MBA at Harvard Business School as part of a fully-funded fellowship. Through this combined experience, he started to develop a niche in the oncology space where clinical, business and policy decisions intersect, at a time when value-based care was just starting to gain momentum.After a fellowship at Memorial Sloan Kettering Cancer Center, Dr. Schleicher joined Tennessee Oncology, one of the nation's largest community-based cancer care practices, and shortly after became medical director of value-based care at OneOncology, a large community oncology network founded by Tennessee Oncology that spans multiple states. He subsequently returned his focus to Tennessee Oncology where he served as chief medical officer for two years and still practices as a breast cancer medical oncologist. Dr. Schleicher is also a board member and executive committee member at the Community Oncology Alliance.To set the stage for a Healthcare is Hard series focused on Oncology, Dr. Schleicher talked to Keith Figlioli about both the clinical and business trends influencing cancer care. Topics they discussed include:Community providers vs. health systems. For Dr. Schleicher, the ultimate goal is to give cancer patients the personal feel of a community clinic with the resources – including access to precision medicine and clinical trials – that have historically only existed at academic medical centers. While Dr. Schleicher firmly believes that nearly all cancer care should be delivered outside the hospital, he recognizes the expertise for certain conditions – like rare sarcomas – that only exists at academic medical centers and discussed the dynamics of “coopetition” that exists between health systems and community providers in markets across the country.Oncology's cost center. Drugs already account for a significant portion of spending on oncology care, and with dozens of new FDA approvals for cancer therapies each year – some with extremely high costs – this trend will continue. But there are many other variables contributing to the large percentage of spending that goes towards drugs, including the shift from infusions to more oral medication. Dr. Schleicher explains how reliance on oral medication introduces PBMs and specialty pharmacies into the equation, which can add cost and complexity, and sometimes slow the speed of critical care.The value based care dilemma. Dr. Schleicher talked about how successful The CMS Oncology Care Model (OCM) was at optimizing care for Tennessee Oncology's patients. He says hospitalizations and ER visits went from 20%-30% of costs before OCM to less than 10% now. The remaining 90% of costs now goes towards drugs – even when used appropriately following pathways. The dilemma is that there isn't too much more room for cost improvement in care delivery. Dr. Schleicher discussed how payers need a better understanding of how to incentivize providers around costs they can control, while allowing for expensive therapies if they're the right drug at the right time to improve costs and outcomes in the long run.To hear Stephen and Keith discuss these topics and more, listen to this episode of Healthcare is Hard: A Podcast for Insiders.

How prepared should you be? Maybe Over-prepared? What to do with your trainees and why it wise to buy time (if you can).

CancerNetwork, in a partnership with KidneyCAN, spoke with 2 genitourinary oncologists, Elizabeth P. Henske, MD, and Jason Muhitch, PhD, about how advocacy and funding through interdisciplinary collaboration between patient advocates, researchers, and physicians have resulted in numerous clinical breakthroughs in kidney cancer.  Henske is a professor of medicine at the Harvard Medical School, an associate member of the Broad Institute of MIT and Harvard, director of the Center for LAM Research and Clinical Care, and a physician at Brigham and Women's Hospital and Dana-Farber Cancer Institute. Muhitch is an associate professor of Oncology, co-chair of the Genitourinary Translational Research Group, deputy director of Graduate Studies, and a member of the Department of Immunology at Roswell Park Comprehensive Cancer Center at Roswell Park Comprehensive Cancer Center. First, the state of kidney cancer advocacy was discussed, with Muhitch emphasizing multidisciplinary collaboration and the role of conferences, such as the Kidney Cancer Research Summit (KCRS) and the International Kidney Cancer Symposium, in bringing these groups together. Henske emphasized the strength of the advocacy network for kidney cancer, particularly as a mechanism for exchanging information, offering patient support and education, and facilitating research. Next, funding was touched upon, with Henske expressing her interest in conveying the importance and urgency of kidney cancer research to Congress. Muhitch agreed, suggesting that the meetings with congressional offices offer opportunities to explain how funding can impact kidney cancer outcomes and scientist training, as well as the strength of patient advocacy in influencing Congress. Muhitch and Henske then discussed the Kidney Cancer Research Program, which has enabled significant increases in funding for kidney cancer research, helped to facilitate clinical breakthroughs for common kidney cancer types, and set a foundation for exploring different kidney cancer variants. The discussion then turned to encouraging research for renal cell carcinoma , which Muhitch expressed can be attributed to partnership award recipients who went on to conduct research evaluating biomarkers predictive of patient responses to immunotherapies.  Regarding additional funding mechanisms, Henske and Muhitch discussed numerous private foundations providing smaller research grants. Henske explained that these smaller grants are instrumental in taking the first steps to explore rarer kidney cancer subtypes, with Muhitch explaining that the earlier funding can formulate research that leads to greater funding from the Kidney Cancer Research Program. KidneyCAN is a nonprofit organization with a mission to accelerate cures for kidney cancer through education, advocacy, and research funding. Learn more about KidneyCAN's mission and work here.

“… If it's garbage in, it's gonna be garbage out.” Boy, am I familiar with that truth. And it prevails across so many areas of healthcare, but maybe none more ...

In this episode of Southern Medicine, Dr. Sadie Elisseou, an internationally recognized subject matter expert in trauma-informed care (TIC), will highlight specific examples of how healthcare professionals can apply the Substance Abuse and Mental Health Service (SAMHSA)'s “4 Rs” and “6 principles” of TIC to clinical care and their own well-being. Listeners will leave with simple, actionable steps to ensure that care provided is safe, collaborative, and avoids retraumatizing patients.

HealthLeaders Senior Editor for Innovation Eric Wicklund talks to Jim Blum, chief health information officer at the University of Iowa Hospitals & Clinics and a participant in the HealthLeaders Mastermind program on AI in clinical care, on how the health system is using AI and how they're setting the ground rules for future programs.

In the eleventh episode of season 3, Dr. U. Grant Baldwin, Jr., DBH, Director of the Doctor of Behavioral Health program at Cummings Graduate Institute for Behavioral Health Studies, explores how integrating recovery housing with clinical treatment services improves patient outcomes, providing stability and structure for long-term recovery. Our guest shares their journey in developing integrated care models that combine recovery housing with various healthcare disciplines and discusses the challenges and successes they've encountered along the way. Special Guest: Kenneth L. Roberts, MPS, LPCC, LADC, is the Chief Clinical Officer for the NUWAY non-profit program in Minneapolis, MN. He has worked for over 15 years as a clinician, clinical supervisor, and administrator in various levels of co-occurring care treating substance use and mental health disorders. He is certified in Prolonged Exposure (PE) and Accelerated Resolution Therapy (ART) for treatment of PTSD. A graduate of the University of Minnesota with a master's degree in Professional Studies (Co-Occurring Disorders) he also serves as an adjunct faculty member at the University of Minnesota. Mr. Roberts works in his current role synthesizing a R.I.S.E. (Recovery In Supportive Environments) Model of care with community based resources to support improved clinical outcomes in trauma informed care settings. Mr. Roberts is currently a Doctoral candidate (DBH) at the Cummings Graduate Institute (CGI). --- Support this podcast: https://podcasters.spotify.com/pod/show/disruptors-at-work/support

ABOUT THIS EPISODE (+ scroll for resources)

What is the “best way” to take history, talking about patients expectations and what you must do before calling your consultants.

Chris Hughen sat down with Ilana Ackerman to discuss Knee Osteoarthritis. We dive into the contents of the newly updated Osteoarthritis of the Knee Clinical Care Standard based out of Australia. Ilana outlines the 8 quality statements within the Clinical Care Standard, communication and management strategies, what treatments are not appropriate / recommended for knee OA, and much more. Watch the full episode: https://youtu.be/qr2Xx6pO10Q  Resources:  OA of the Knee Clinical Care Standard Knee OA Fact Sheets More about Ilana:  Ilana's ResearchGate Ilana's Twitter --- Follow Us: YouTube: https://www.youtube.com/e3rehab  Instagram: https://www.instagram.com/e3rehab/ Twitter: https://twitter.com/E3Rehab --- Rehab & Performance Programs: https://store.e3rehab.com/  Newsletter: https://e3rehab.ck.page/19eae53ac1  Coaching & Consultations: https://e3rehab.com/coaching/  Articles: https://e3rehab.com/articles/  Apparel: https://store.e3rehab.com/collections/frontpage  --- Podcast Sponsors: Legion Athletics: Get 20% off using "E3REHAB" at checkout! - https://legionathletics.rfrl.co/wdp5g  Vivo Barefoot: Get 15% off all shoes! - https://www.vivobarefoot.com/e3rehab Tindeq: Get 10% off your dynamometer using code “E3REHAB” at checkout - https://tindeq.com/ --- @dr.surdykapt @tony.comella @dr.nicolept @chrishughen @nateh_24 --- This episode was produced by Matt Hunter

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWU865. CME credit will be available until September 23, 2025.Are We Closer to a Cure With Perioperative Immunotherapy in Resectable NSCLC? Latest Evidence, Current Conclusions, and Ongoing Questions in Clinical Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

Sometimes it is good to give your patients (or parents) some options regarding their care (some people call it shared decision making). How a short conversation can help you better understand your patients and their needs.

Many clinicians believe that simply offering quality care is enough to grow their practices, but this isn't always the case. If you're a clinic owner, a contractor, or a clinician, you may find yourself stuck in a cycle where despite your best efforts, patient flow and revenue generation don't seem to match up with the quality of care you provide.   When clinics rely solely on word-of-mouth or outdated marketing techniques, they often fall short of reaching their full potential. Darryll E. Gardley, an experienced physical therapist, clinic owner, and mentor, joins us to share his expertise on how to break free from this mold and build a thriving, revenue-generating practice.   BY THE TIME YOU FINISH LISTENING, YOU'LL DISCOVER:   How to strategically communicate your clinic's unique offerings to attract your ideal patient base. Proven in-house strategies to empower your staff and boost clinic performance. Outsourcing tips to maximize efficiency and maintain a balanced work-life integration. Insightful collaboration techniques to enhance patient outcomes and build a strong referral network.   If you're ready to take your practice to the next level and redefine how you operate in the clinical space, this episode is for you. Don't miss out!   Connect with Darryl: Instagram: https://www.instagram.com/darrylyardley/ Linktree: https://linktr.ee/darrylyardley Let's connect!   Instagram:@natasha.wilchEmail: hello@natashawilch.com Website: https://www.natasha-wilch.com   Episode Sponsor: JANE APP To learn more about how Jane's intake forms can help, head to jane.app/guide to book a 1-on-1 demo with a member of their team. If you're ready to get started, you can use the code SYMPHONY1MO at the time of sign-up to get a 1-month grace period applied to your new account.   Be the FIRST to know all the information for our upcoming CONCUSSION NERDS VIRTUAL SUMMIT this fall by joining the waitlist HERE https://www.natashawilch.com/summit-waitlist

226: Nutrition Training for Healthcare Providers: Bridging the Gap Host: Dr. Ali Novitsky Welcome to another exciting episode of the Muscles & Mindset Podcast! Dr. Ali Novitsky is thrilled to dive into a topic that is both her passion and profession: nutrition. This episode is particularly special as it focuses on bridging the gap in nutrition knowledge for healthcare providers. Introduction Dr. Novitsky begins the episode by sharing a bit about her background and lifelong fascination with nutrition. From a young age, she was deeply interested in how food and exercise impact our bodies. This passion led her to accumulate a vast library of nutrition books and spend weekends discussing diets at GNC. Her journey has been shaped by personal experiences, including being an overweight child, which fueled her interest in nutrition and exercise. The Importance of Nutrition in Healthcare She discusses the critical role nutrition plays in both preventing and treating diseases. Despite its importance, traditional medical training often lacks comprehensive nutrition education, leaving many healthcare providers feeling unprepared to offer nutritional advice to their patients. Dr. Novitsky emphasizes that while doctors are trained to save lives, they are not typically trained to be nutrition experts. Unique Approach Over the years, she has developed a unique approach to nutrition, which she calls "Mindful Macros." This program is designed to make nutrition simple and effective. Dr. Novitsky believes that understanding and implementing basic nutrition strategies can save lives and aims to empower healthcare providers with the knowledge and tools needed to offer sound nutritional advice to their patients. Introducing the Eight Week Nutition Training Program She is excited to announce a new eight-week training program specifically designed for healthcare providers. This program will cover everything she has learned and implemented in her coaching programs over the past several decades. The training will be live, offering participants the opportunity to interact with her and ask questions. Additionally, esteemed colleagues like Dr. Matthea Rentea will contribute her expertise, particularly in areas like obesity medicine and post-bariatric care. Overcoming Obstacles Dr. Novitsky addresses several obstacles that healthcare providers face when it comes to nutrition: Lack of Training: Most medical schools do not offer extensive nutrition education. Time Constraints: Healthcare providers are often too busy to prioritize their own nutrition, let alone advise patients. Simplifying: The plethora of nutrition strategies out there can be overwhelming and at times, contradictory. She assures listeners that her program is designed to make nutrition advice simple and actionable, even for the busiest healthcare providers. Program Details The eight-week program will officially start on October 7th, but early enrollees will gain immediate access to bonus content, including the emotional eating and body composition training series. Participants will also receive a comprehensive provider nutrition training manual and a nutrition audit guide, making it easy to implement these strategies in their practice. Conclusion Dr. Novitsky wraps up the episode by encouraging healthcare providers to sign up for the program. She believes that by bridging the gap in nutrition knowledge, a significant impact can be made on public health. The program offers 12 CMEs for physicians and provides year-long access to all content. For more details and to enroll, visit [thefitcollective.com/nutrition-training]. Thank you for tuning in, and Dr. Novitsky can't wait to help transform your approach to nutrition and healthcare! Until next time, stay healthy and keep learning! Timestamps 00:00:00 - Introduction to Muscles & Mindset Podcast 00:00:20 - Excitement About Nutrition 00:00:32 - Family Background and Sibling Talents 00:01:05 - Brother Chris: The Pulmonary Critical Care Doctor 00:02:00 - Brother Matt: The Internal Medicine Doctor 00:02:43 - Ali's Early Interest in Nutrition 00:03:36 - Teenage Years: Building a Nutrition Library 00:04:09 - Importance of Trying Nutrition Protocols 00:04:40 - Bridging the Gap in Nutrition and Clinical Care 00:05:02 - Medical Training and Nutrition Knowledge 00:06:06 - Importance of Nutrition in Saving Lives 00:07:09 - Eight-Week Training Program for Healthcare Professionals 00:08:04 - Special Cases in Nutrition Management 00:08:46 - Obstacles in Medical Training and Nutrition 00:09:08 - Environmental and Genetic Factors in Nutrition 00:10:02 - Differences in Dairy Between Europe and the U.S. 00:11:07 - Personal Experiment with A2 Milk 00:11:39 - Challenges for Healthcare Providers 00:12:00 - Simplifying Nutrition Advice for Patients 00:13:04 - Flexibility in Nutrition Approaches 00:14:07 - Time Constraints for Healthcare Providers 00:15:01 - Making Nutrition Simple and Effective 00:15:46 - Empowering Healthcare Providers with Nutrition Knowledge 00:16:07 - Preventative Health and Nutrition 00:17:10 - Personal Story: Chronic Benign Neutropenia 00:18:02 - Six-Week Program Details and Access 00:19:05 - Provider Nutrition Training Manual 00:20:09 - Nutrition Audit Guide 00:21:04 - Bridging the Gap in Healthcare with Nutrition and Exercise 00:21:36 - Enrollment Information and Bonus Content Resources The Muscles & Mindset Program - 12 months for only $199! Enroll TODAY. Nutrition Training Program for Healthcare Providers is enrolling now! You can learn more HERE. Dr. Ali's Advanced Strength Training program is now available for exercises at a higher level. See the details HERE. Optimal GLP-1 Weight Loss Program - next program starts November, 2024.  Learn more and join the waitlist HERE. Transform® 9.0 enrollment is open for a January, 2025 waitlist. Follow Dr. Ali Novitsky on TikTok | Facebook | Instagram | YouTube Subscribe to The Muscles and Mindset Podcast on Spotify | Apple Podcasts *Ali Novitsky MD, this podcast, and podcast write-up are NOT providing medical advice. We do not recommend you start any exercise program without first consulting with your doctor!*

On today's episode, I'm joined by Dr. Alan Fredendall as part of our CrossFit series to discuss the power of the CrossFit methodology for health promotion and the growth of fitness-forward clinical care. Alan is a father, husband, physical therapist, CrossFit Level 3 coach, and educator. He serves as Chief Operator Officer and the division leader of the Clinical Management of the Fitness Athlete (CMFA) and Practice Management divisions at ICE Physio. He co-owns & operates his own outpatient physical therapy clinic, HealthHQ, in Michigan where he also coaches & participates in CrossFit next door at CrossFit Fenton. . In today's conversation, you'll hear about Alan's personal fitness transformation from weighing 400 pounds to becoming a fitness junkie, the art of creating habit change and helping others get active, what makes the local CrossFit affiliate a breeding ground for setting and achieving long term health and fitness goals, and so much more. If you're curious about CrossFit OR have somebody in your life that you want to help get healthy, this is the episode for you. Enjoy my conversation with Alan.  Alan's Links: Instagram: https://www.instagram.com/alan.fred.dpt/ ICE Physio: https://ptonice.com/ Health HQ: https://healthhq.fit/ Julie's Links:  https://thegoalsetmindset.com/ Instagram:  https://www.instagram.com/goalsetmindset_jb/ Shownotes: 05:30- Introduction & The Early Days of ICE 09:10- The Start of Alan's Fitness Journey, Losing 200 Pounds, and Joining the Army 16:15- What made you finally accept an invite to CrossFit? What your initial experience like? 26:30- “80% of people in our country aren't doing any fitness. We need to market to THAT person.” 29:45- “If we're going to create habit change with people I do think it needs to be fun. It can't be this fertile, quiet environment… it has to trigger a positive emotion.” 32:00- Many people perceive CrossFit as “crazy” or “dangerous”. What is your response to this? 38:45- “If you want to live both a long and a high quality life, some discomfort has to come into the equation somewhere.” 46:15- Moving Patients along the Sickness-Wellness-Fitness Continuum 54:00- Defining “Constantly Varied, High-Intensity, Functional Fitness”

Sharon Desmond, Group Manager for Caring for People & Planet at Mercy Health, discusses Mercy Health's strategy for developing sustainable models of clinical care. This session was recorded at the Sustainable Healthcare Workshop workshop at CODA22 which took place in Melbourne in September 2022. For more information about the CODA Project go to: https://codachange.org/ 

Featuring perspectives from Ms Jamie Carroll, Ms Kelly EH Goodwin, Dr Erika Hamilton and Dr Hope S Rugo, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs); HER2-Targeted ADCs for Breast Cancer — T-DM1, Trastuzumab Deruxtecan (7:22) The Incidence and Management of Interstitial Lung Disease with ADCs (34:05) ADCs Targeting Other Signaling Pathways in Breast Cancer — Sacituzumab Govitecan, Datopotamab Deruxtecan, Patritumab Deruxtecan (49:02) ADCs for Other Tumor Types and Toxicities Associated with ADCs (1:14:53) NCPD information and select publications

Featuring perspectives from Dr Harold J Burstein, Ms Kelly Fischer, Dr Komal Jhaveri and Ms Melissa Rikal, including the following topics: Introduction (0:00) The Utility of Genomic Assays in Treatment Decision-Making for HR-Positive, HER2-Negative Localized Breast Cancer (10:21) The Role of CDK4/6 Inhibitors in Therapy for HR-Positive Breast Cancer (37:18) Oral Selective Estrogen Receptor Degraders in the Management of HR-Positive Metastatic Breast Cancer (mBC) (1:04:27) Alpelisib and Capivasertib in Treatment for HR-Positive mBC (1:28:40) NCPD information and select publications

Dr. Diane Reidy-Lagunes is a top NYC Oncologist from Memorial Sloan Kettering Cancer Center. She is the creator and host of the award-winning monthly podcast Cancer Straight Talk from MSKCC where she leans in and tackles the subject of cancer head on, in English and Spanish. A noted clinical investigator, Diane served previously as President of MSK's Medical Staff. She currently serves as Vice Chair in the Department of Medicine. During the COVID crisis in NYC, she served as Chief of Clinical Care as part of the Hospital Incident Command System. As a researcher, she focuses on developing treatments of gastrointestinal (GI) tumors. She is a member of the National Cancer Institute Taskforce and a member of the National Cancer Care Network Guidelines. She is the recipient of several honors, including the Paul Sherlock Teaching Award, Castle Connolly Top Doctors, and the American Cancer Society Mother of the Year Award. In addition, Diane maintains a high-volume GI Oncology clinic.You can find her podcast Cancer Straight Talk at https://www.mskcc.org/cancerstraighttalk. This episode is part of a special series in collaboration between The Fiftyfaces Podcast at fiftyfaceshub.com and The Mindshare Podcast at www.monumentalme.com/podcast. --- Support this podcast: https://podcasters.spotify.com/pod/show/mindshare/support

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

If you are wondering about the future role of AI in clinical care, this is an episode you must listen to. In this episode co-hosted with MohammadAli Jardaly, we discuss with the integration of AI into clinical care with Dr. Hussain Ismaeel (who is the co-founder of Healtech). He is involved in developing SOLVIT, an AI based clinical practice management product. We discuss the role this product will have in streamlining clinical practice management, and its role in data analysis and research. #artificialintelligence #clinicalpractice #aihealthcare This episode is also available on all podcast apps and on YouTube

Featuring perspectives from Ms Deanna A Griffie, Ms Caroline Kuhlman, Dr Manish A Shah and Dr John Strickler, including the following topics: Introduction (0:00) The Current Role of Anti-PD-1/PD-L1 Antibodies in the Management of Nonmetastatic Gastroesophageal Cancers (11:30) The Potential Role of Immune Checkpoint Inhibitors (ICIs) as Neoadjuvant Therapy for Patients with Gastric/Gastroesophageal Junction Cancer (20:53) First-Line Therapy for Metastatic Gastroesophageal Cancers (36:16) The Potential Role of Therapy Targeting Claudin 18.2 for Gastroesophageal Cancers (42:16) Targeted Therapies for HER2-Positive Gastroesophageal Cancers (51:42) Selection of Appropriate Candidates with Localized Colorectal Cancer (CRC) for Adjuvant Therapy (1:14:24) The Current Role of ICIs in the Treatment of Metastatic CRC (mCRC) (1:23:32) Tolerability and Other Practical Considerations with ICIs (1:25:57) The Role of TAS-102/Bevacizumab in the Management of Relapsed/Refractory (R/R) mCRC (1:36:14) The Potential Role of KRAS-Targeted Therapy in the Management of mCRC (1:44:36) NCPD information and select publications

Featuring perspectives from Ms Ilene Galinsky, Dr Andrew T Kuykendall, Dr Sara M Tinsley-Vance and Dr Abdulraheem Yacoub, including the following topics: Introduction (0:00) The Biology of Myelofibrosis (MF) (14:00) Role of Available and Investigational JAK inhibitors for the Management of MF (45:49) Promising Agents and Strategies for Patients with MF (1:23:17) NCPD information and select publications

Featuring perspectives from Ms Courtney Arn, Dr Floor J Backes, Dr Kathleen N Moore and Ms Jaclyn Shaver, including the following topics: Introduction: The Incidence, Pathogenesis and Prognosis of Ovarian Cancer (0:00) Genetic Testing for Newly Diagnosed Advanced Ovarian Cancer (11:01) The Role of PARP Inhibitor Maintenance for Newly Diagnosed Advanced Ovarian Cancer (19:02) Side Effects Associated with PARP Inhibitors (29:58) Dosing, Adherence and Other Issues with PARP Inhibitors for Ovarian Cancer (48:29) The Potential Role of PARP Inhibitors in Combination with Anti-PD-1/PD-L1 Antibodies for Advanced Ovarian Cancer Management (54:11) PARP Inhibitors for Relapsed/Refractory Ovarian Cancer (1:00:36) The Current Role of Mirvetuximab Soravtansine for Ovarian Cancer Treatment (1:07:14) Toxicities with Mirvetuximab Soravtansine (1:11:53) The Incidence and Management of HER2-Positive Ovarian Cancer (1:18:18) NCPD information and select publications

Sometimes (it is not often), a normal physical exam is actually more concerning, why it is a good idea to be pessimistic? and how to be comfortable with risks?    

Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics: Introduction (0:00) The Biology of Head and Neck Cancer (15:41) The Multidisciplinary Treatment of Head and Neck Cancer (18:14) Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03) Radiation Therapy and Chemotherapy Side Effects (41:02) The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50) Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46) Tolerability Considerations with Xevinapant (1:06:13) The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35) Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27) The Tolerability of Immune Checkpoint Inhibitors (1:24:09) NCPD information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics: Introduction (0:00) Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40) Role of Immunotherapy in Intermediate-Stage HCC (17:02) First-Line Therapy for Advanced HCC (19:56) Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29) Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02) Potential Role of HER2-Targeted Therapy for BTCs (1:17:16) CME information and select publications  

Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O'Malley and Dr Shannon N Westin, including the following topics: Introduction (0:00) Incidence and Biology of Endometrial Cancer (EC) (9:30) Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24) First-Line Therapy for Primary Advanced or Recurrent EC (28:28) Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08) Potential Role of Selinexor in the Management of EC (1:13:20) Incidence and Management of HER2-Positive EC (1:22:51) NCPD information and select publications

Featuring perspectives from Dr Andrew J Armstrong and Ms Brenda Martone, including the following topics: Introduction: Overview of Prostate Cancer; Hormonal Therapy (0:00) Radiopharmaceuticals for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) (24:11) Biomarker Testing for mCRPC; PARP Inhibitors for mCRPC (49:33) NCPD information and select publications

This presentation features Victoria Brazil and took place during the Clinical stream at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/

This presentation was delivered by David Anderson as part of the Clinical stream at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/

Featuring perspectives from Ms Marianne J Davies, Dr Alexander I Spira, Ms Jillian Thompson and Dr Helena Yu, including the following topics: Introduction (0:00) The Importance of EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) (7:02) The Role of Osimertinib in Managing Localized and Locally Advanced NSCLC with an EGFR Mutation (11:58) Established First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (32:38) Newly Approved and Promising Investigational Approaches to First-Line Therapy for Metastatic NSCLC with an EGFR Mutation (37:45) Common Toxicities Associated with Amivantamab (45:07) The Current and Future Management of Progressive NSCLC with an EGFR Mutation (55:06) Tolerability and Other Practical Considerations with HER3-DXd (1:01:06) Treatment for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations (1:18:26) CME information and select publications

This presentation was delivered by Eric Levi as part of the Clinical stream at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/

Sometimes there are "odd reasons" for using a test, Getting a good history is key and some questions are more important than others and a bit about knowing what not to do.        Please consider contributing to PEM Rules at https://ko-fi.com/pemrules And check out www.pemrules.com    Copyright PEM Rules LLC       DISCLAIMER By listening to this podcast, you agree not to use these resources as medical advice to treat any medical conditions in either yourself or others, including, but not limited to, patients that you are treating. Consult your own physician for any medical issues that you may be having. This entire disclaimer also applies to any guests or contributors to the podcast or website. Under no circumstances shall PEM Rules, the PEM Rules podcast or any guests or affiliated entities be responsible for damages arising from their use. This podcast should not be used in any legal capacity whatsoever, including, but not limited to, establishing “standard of care” in a legal sense or as a basis for expert witness testimony. No guarantee is given regarding the accuracy of any statements or opinions made on the website or in the podcast.  

This presentation was delivered by Alex Psirides as part of the Clinical Care stream at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/

Gemma Figtree, Mya Cubitt, and Greg Kelly answer questions from the audience during the Clinical stream at CODA22, which took place in Melbourne in September 2022.  For more information about the CODA Project go to: https://codachange.org/